| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Eun-Joo Shin, Jin Hyeong Jhoo, Toshitaka Nabeshima, Wang-Kee Jhoo, Myung Sang Kwon, Yong Kwang Lim, Jong Seok Chae, Myung Eun Jung, Seok Joo Park, Kyung Jin Jang, Hyoung-Chun Ki. Growth hormone releaser attenuates beta-amyloid (1 - 42)-induced memory impairment in mice. Journal of pharmacological sciences. vol 99. issue 1. 2006-05-03. PMID:16141634. |
in this study, mice that were fed with a diet of gh-releasing supplements had significantly attenuated memory impairments and hippocampal changes in the acetylcholinesterase activity and acetylcholine level induced by amyloid beta protein (abeta) (1 - 42). |
2006-05-03 |
2023-08-12 |
mouse |
| Rehan Baqri, Rakshita Charan, Kristina Schimmelpfeng, Swati Chavan, Krishanu Ra. Kinesin-2 differentially regulates the anterograde axonal transports of acetylcholinesterase and choline acetyltransferase in Drosophila. Journal of neurobiology. vol 66. issue 4. 2006-04-28. PMID:16408306. |
choline acetyltransferase (chat) and acetylcholinesterase (ache) are involved in acetylcholine synthesis and degradation at pre- and postsynaptic compartments, respectively. |
2006-04-28 |
2023-08-12 |
drosophila_melanogaster |
| J Birk. Cholinesterase inhibitors for Alzheimer's disease. The Cochrane database of systematic reviews. issue 1. 2006-04-07. PMID:16437532. |
since the introduction of the first cholinesterase inhibitor (chei) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate alzheimer's disease.the drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase. |
2006-04-07 |
2023-08-12 |
Not clear |
| C M Hernandez, D A Gearhart, V Parikh, E J Hohnadel, L W Davis, M L Middlemore, S P Warsi, J L Waller, A V Terr. Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats. The Journal of pharmacology and experimental therapeutics. vol 316. issue 2. 2006-04-04. PMID:16214877. |
this study was designed to determine 1) whether repeated exposures to the acetylcholinesterase inhibitors (acheis) galantamine (gal) or donepezil (don) resulted in positive effects on nerve growth factor (ngf) and its receptors, cholinergic proteins, and cognitive function in the aged rat, and 2) whether gal had any advantages over don given its allosteric potentiating ligand (apl) activity at nicotinic acetylcholine receptors. |
2006-04-04 |
2023-08-12 |
rat |
| Daquan Gao, Chang-Guo Zha. Modeling evolution of hydrogen bonding and stabilization of transition states in the process of cocaine hydrolysis catalyzed by human butyrylcholinesterase. Proteins. vol 62. issue 1. 2006-03-31. PMID:16288482. |
the computational results consistently reveal a unique role of the oxyanion hole (consisting of g116, g117, and a199) in bche-catalyzed hydrolysis of cocaine, compared to acetylcholinesterase (ache)-catalyzed hydrolysis of acetylcholine. |
2006-03-31 |
2023-08-12 |
human |
| Gerald D Silverberg, Martha Mayo, Thomas Saul, Joan Carvalho, Dawn McGuir. Novel ventriculo-peritoneal shunt in Alzheimer's disease cerebrospinal fluid biomarkers. Expert review of neurotherapeutics. vol 4. issue 1. 2006-03-29. PMID:15853620. |
treatment is symptomatic, consisting of compounds that block enzymatic acetylcholine degradation (acetylcholinesterase inhibitors). |
2006-03-29 |
2023-08-12 |
Not clear |
| David E Kuhl, Robert A Koeppe, Scott E Snyder, Satoshi Minoshima, Kirk A Frey, Michael R Kilbour. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses. Annals of neurology. vol 59. issue 1. 2006-03-23. PMID:16278840. |
we tested the premise that cholinesterase inhibitor therapy should target butyrylcholinesterase (buche) in alzheimer's disease (ad), not acetylcholinesterase (ache) alone, because both enzymes hydrolyze acetylcholine, and buche is increased in ad cerebral cortex. |
2006-03-23 |
2023-08-12 |
Not clear |
| Lucie Bartosova, Kamil Kuca, Daniel Jun, Gabriela Kunesov. Bispyridinium oximes as antidotal treatment of cyclosarin poisoning-in vitro and in vivo testing. International journal of toxicology. vol 24. issue 6. 2006-03-15. PMID:16393932. |
the mechanism of intoxication with organophosphorus compounds, including highly toxic nerve agents and less toxic pesticides, is based on the formation of irreversibly inhibited acetylcholinesterase, which causes cumulation of neuromediator acetylcholine in synaptic clefts and subsequent overstimulation of cholinergic receptors, that is followed by a generalized cholinergic crisis. |
2006-03-15 |
2023-08-12 |
mouse |
| Lucie Bartosova, Kamil Kuca, Daniel Jun, Gabriela Kunesov. Bispyridinium oximes as antidotal treatment of cyclosarin poisoning-in vitro and in vivo testing. International journal of toxicology. vol 24. issue 6. 2006-03-15. PMID:16393932. |
nerve agent poisoning is conventionally treated using a combination of a cholinolytic (atropine mostly) to counteract the accumulation of acetylcholine and acetylcholinesterase reactivators (pralidoxime or obidoxime) to reactivate inhibited acetylcholinesterase. |
2006-03-15 |
2023-08-12 |
mouse |
| Allan T Gulledge, Greg J Stuar. Cholinergic inhibition of neocortical pyramidal neurons. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 25. issue 44. 2006-03-13. PMID:16267239. |
furthermore, eserine, an acetylcholinesterase inhibitor similar to those used therapeutically in the treatment of alzheimer's disease, disproportionately enhanced the excitatory actions of acetylcholine while reducing the ability of acetylcholine to generate inhibitory responses during repeated applications of ach. |
2006-03-13 |
2023-08-12 |
rat |
| J M Rollinger, P Mocka, C Zidorn, E P Ellmerer, T Langer, H Stuppne. Application of the in combo screening approach for the discovery of non-alkaloid acetylcholinesterase inhibitors from Cichorium intybus. Current drug discovery technologies. vol 2. issue 3. 2006-03-10. PMID:16472227. |
because of the direct correlation of cholinergic deficit and the severity of dementia, alzheimer's disease is preferentially treated with acetylcholinesterase (ache) inhibitors to supplement the acetylcholine level. |
2006-03-10 |
2023-08-12 |
Not clear |
| Terrone L Rosenberry, Joseph L Johnson, Bernadette Cusack, Jamie L Thomas, Sujata Emani, Kunisi S Venkatasubba. Interactions between the peripheral site and the acylation site in acetylcholinesterase. Chemico-biological interactions. vol 157-158. 2006-02-24. PMID:16256966. |
acetylcholinesterase (ache) hydrolyzes its physiological substrate acetylcholine at one of the highest known catalytic rates. |
2006-02-24 |
2023-08-12 |
Not clear |
| Cecilio J Vida. Expression of cholinesterases in brain and non-brain tumours. Chemico-biological interactions. vol 157-158. 2006-02-24. PMID:16256970. |
although the involvement of cholinesterases (ches) in the removal of acetylcholine (ach) at cholinergic synapses is firmly established, there is evidence to suggest that acetylcholinesterase (ache) and butyrylcholinesterase (buche) take part in several cellular processes. |
2006-02-24 |
2023-08-12 |
Not clear |
| M Guerra, A Cartaud, J Cartaud, C Lega. Acetylcholinesterase and molecular interactions at the neuromuscular junction. Chemico-biological interactions. vol 157-158. 2006-02-24. PMID:16289501. |
we have analyzed the time-course of acetylcholinesterase and acetylcholine receptors (achr) mrnas during mouse muscle cell differentiation in culture. |
2006-02-24 |
2023-08-12 |
mouse |
| Bhupendra P Doctor, Ashima Saxen. Bioscavengers for the protection of humans against organophosphate toxicity. Chemico-biological interactions. vol 157-158. 2006-02-24. PMID:16293236. |
current antidotes for organophosphorus compounds (op) poisoning consist of a combination of pretreatment with carbamates (pyridostigmine bromide), to protect acetylcholinesterase (ache) from irreversible inhibition by op compounds, and post-exposure therapy with anti-cholinergic drugs (atropine sulfate) to counteract the effects of excess acetylcholine and oximes (e.g., 2-pam chloride) to reactivate op-inhibited ache. |
2006-02-24 |
2023-08-12 |
human |
| Laura E Paraoanu, Paul G Laye. Mouse AChE binds in vivo to domain IV of laminin-1beta. Chemico-biological interactions. vol 157-158. 2006-02-24. PMID:16429555. |
functions of acetylcholinesterase (ache) other than hydrolysis of acetylcholine, e.g. |
2006-02-24 |
2023-08-12 |
mouse |
| b' A Komersov\\xc3\\xa1, K Komers, P Zdrazilov\\xc3\\xa. Kinetics of hydrolysis of acetylthiocholine and acetylcholine by cholinesterases. Chemico-biological interactions. vol 157-158. 2006-02-24. PMID:16498728.' |
kinetics of hydrolysis of acetylthiocholine (atch) and acetylcholine (ach) by butyrylcholinesterase (bche) and acetylcholinesterase (ache) are studied. |
2006-02-24 |
2023-08-12 |
Not clear |
| Bryan F Curtin, Lauren M Tetz, Jaimee R Compton, Bhupendra P Doctor, Richard K Gordon, Madhusoodana P Nambia. Histone acetylase inhibitor trichostatin A induces acetylcholinesterase expression and protects against organophosphate exposure. Journal of cellular biochemistry. vol 96. issue 4. 2006-02-21. PMID:16149071. |
the biological effects of organophosphorous (op) chemical warfare nerve agents (cwnas) are exerted by inhibition of acetylcholinesterase (ache), which prevents the hydrolysis of the neurotransmitter acetylcholine, leading to hypercholinergy, seizures/status epilepticus, respiratory/cardiovascular failure, and potentially death. |
2006-02-21 |
2023-08-12 |
human |
| G Grön, I Brandenburg, A P Wunderlich, M W Riep. Inhibition of hippocampal function in mild cognitive impairment: targeting the cholinergic hypothesis. Neurobiology of aging. vol 27. issue 1. 2006-02-14. PMID:16298243. |
we hypothesized that cholinergic malfunction may underlie memory impairment in these subjects and applied a low dosage of an acetylcholinesterase inhibitor and modulator of nicotinic acetylcholine receptors, galantamine (4 mg bid), for 7 days. |
2006-02-14 |
2023-08-12 |
human |
| Toshiaki Kume, Mitsuhiro Sugimoto, Yuki Takada, Toshiaki Yamaguchi, Atsushi Yonezawa, Hiroshi Katsuki, Hachiro Sugimoto, Akinori Akaik. Up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons. European journal of pharmacology. vol 527. issue 1-3. 2006-02-08. PMID:16313899. |
up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons. |
2006-02-08 |
2023-08-12 |
rat |